LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Harvard Bioscience Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.54 -8.47

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.53

Max

0.6

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.1M

-1.2M

Pardavimai

141K

21M

Pelno marža

-5.978

Darbuotojai

330

EBITDA

1M

1.2M

Dividendai

By Dow Jones

Kitas uždarbis

2026-03-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-1.9M

24M

Ankstesnė atidarymo kaina

9.01

Ankstesnė uždarymo kaina

0.54

Naujienos nuotaikos

By Acuity

17%

83%

23 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Harvard Bioscience Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-11 23:47; UTC

Karštos akcijos

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026-02-11 22:59; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Grab Holdings to Buy U.S.-Based Stash Financial

2026-02-11 23:54; UTC

Uždarbis

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026-02-11 23:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-11 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026-02-11 23:49; UTC

Uždarbis

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026-02-11 23:45; UTC

Uždarbis

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026-02-11 23:42; UTC

Uždarbis

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026-02-11 23:41; UTC

Uždarbis

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026-02-11 23:40; UTC

Uždarbis

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026-02-11 23:35; UTC

Rinkos pokalbiai

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026-02-11 23:18; UTC

Rinkos pokalbiai

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026-02-11 23:14; UTC

Rinkos pokalbiai

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026-02-11 22:59; UTC

Uždarbis

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026-02-11 22:58; UTC

Uždarbis

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026-02-11 22:57; UTC

Uždarbis

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026-02-11 22:54; UTC

Uždarbis

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026-02-11 22:53; UTC

Uždarbis

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:47; UTC

Uždarbis

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026-02-11 22:23; UTC

Uždarbis

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026-02-11 22:22; UTC

Uždarbis

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026-02-11 22:19; UTC

Uždarbis

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026-02-11 22:18; UTC

Uždarbis

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026-02-11 22:16; UTC

Uždarbis

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Akcijų palyginimas

Kainos pokytis

Harvard Bioscience Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.3 / 0.3401Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

No Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

23 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat